查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933346

全球百白破（白喉、破伤风和百日咳）疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 请询问到货日

价格

百白破（白喉、破伤风和百日咳）疫苗市场成长因素

由于疫苗可预防细菌性疾病的增加和全球免疫活动的扩大，全球百白破（白喉、破伤风和百日咳）疫苗市场正经历强劲增长。根据 Fortune Business Insights 的数据显示，2025 年全球百白破疫苗市值为 116.9 亿美元。预计该市场将从 2026 年的 134.4 亿美元成长到 2034 年的 464.6 亿美元，在预测期内复合年增长率高达 16.77%。 北美将在2025年以40.92%的市占率引领全球市场，这主要得益于其高疫苗接种率和完善的医疗保健基础设施。

DTP疫苗是一种联合疫苗，可预防三种严重的细菌感染：白喉、破伤风和百日咳。这些疫苗有多种形式，例如DTaP、Tdap和DT/Td疫苗，广泛用于婴幼儿、儿童、青少年、成人和孕妇。与这些疾病相关的严重併发症，包括肺炎、抽搐、气道阻塞和肌肉痉挛，显着增加了全球疫苗的需求。

市场动态

市场驱动因素

细菌性呼吸道感染的日益增加是推动市场成长的主要因素。百日咳由百日咳桿菌引起，具有高度传染性，对婴幼儿构成重大风险。 全球百日咳病例报告数量的增加，促使人们更加关注及时接种疫苗和加强剂。儿童免疫接种计划的重要性日益凸显，政府积极参与疫苗接种项目，进一步推动了市场扩张。

市场限制因子

儘管成长动力强劲，但疫苗犹豫和对疫苗接种计划缺乏了解仍然是挑战，尤其是在低收入国家和发展中地区。宗教信仰、关于疫苗安全性的错误讯息以及医疗基础设施不足，导致错失接种机会和疫苗接种不完整，从而限制了市场成长并增加了疾病爆发的风险。

市场机会

政府主导的疫苗接种计划为市场提供了巨大的成长机会。一些国家正在加强其国家免疫规划，以提高婴幼儿、儿童和成人的疫苗接种覆盖率。国际联盟和组织也积极推广加强剂接种计画和联合疫苗，以减轻疾病负担和降低医疗成本。 这些措施预计将推动疫苗接种率，并支持市场成长至 2034 年。

市场挑战

缺乏冷藏配送基础设施仍然是一项重大挑战，尤其是在资源匮乏的地区。百白破疫苗从储存到运输都需要严格的温度控制。冷藏设施不足和物流不可靠会导致疫苗浪费、效力降低和营运成本增加，从而抑制市场成长。

百白破疫苗市场趋势

疫苗研发技术的进步正在塑造百白破疫苗市场的未来。传统的化学灭活疫苗面临免疫原性降低和需要多次加强免疫等挑战。因此，製造商越来越多地转向重组疫苗技术，该技术具有更高的安全性、更强的免疫反应和更持久的保护作用。预计这些创新将在预测期内显着影响市场成长。

细分市场分析

依技术划分，灭活疫苗市场占主导地位，这得益于已获批准产品的广泛应用和全球较高的疫苗接种率。然而，由于研发活动的增加，重组疫苗和其他先进技术预计将呈现显着成长。

依类型划分，DTaP疫苗市场占有率最大，这得益于其在儿童免疫规划中的广泛应用。 Tdap疫苗市场占有率也相当可观，因为它可作为青少年、成人和孕妇的加强疫苗。

依年龄组别划分，儿童市场占主导地位。这主要归功于早期接种疫苗的强烈建议以及儿童较高的疾病风险。成人市场也贡献显着，这得益于常规加强免疫接种和产前免疫规划。

依分销管道划分，政府供应商市占率最大。这主要得益于国家免疫规划和疫苗批量采购。 由于就医便利性提高，医院和零售药局预计将保持稳定成长。

区域展望

北美地区预计2025年将引领市场。这得益于较高的疾病认知度、强大的疫苗接种覆盖率以及主要市场参与者的存在。

亚太地区占第二大市场占有率，预计将以最高的复合年增长率增长，这主要得益于疾病流行率的上升、政府主导的疫苗接种运动以及价格合理的疫苗供应。

欧洲凭藉先进的医疗保健体系和系统化的疫苗接种计划，继续保持着重要的市场占有率。

拉丁美洲以及中东和非洲地区预计将保持稳定成长，这主要得益于疫苗接种计划的扩大以及为消除疫苗可预防疾病而加大的力度。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 各国主要疾病流行情形（2025 年）
  • 主要产业趋势：新产品发布、併购、业务合作等
  • 主要公司产品线分析
  • 概述：白喉、破伤风和百日咳三重疫苗（DTP）接种率国家/地区

第五章 全球百白破（白喉、破伤风与百日咳）疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依技术分类
    • 灭活​​疫苗
    • 其他
  • 市场分析、洞察与预测：依类型分类
    • DTaP疫苗
    • Tdap疫苗
    • DT/Td疫苗
    • 其他
  • 市场分析、洞察与预测：依年龄组别分类
    • 儿科
    • 成人
  • 市场分析、洞察与预测：依通路分类
    • 医院与零售通路药房
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美百白破疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲百白破疫苗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区百白破疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲百白破疫苗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东和非洲 DTP（白喉、破伤风和百日咳）疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • GSK plc
    • Sanofi
    • Merck &Co., Inc.
    • Boryung Biopharma Co.
    • Serum Institute of India Pvt. Ltd.
    • Wuhan Institute of Biological Products Co., Ltd.
    • BioNet-Asia.
    • Bio Farma
    • Biological E Limited.
Product Code: FBI113648

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is witnessing robust growth due to the rising burden of vaccine-preventable bacterial diseases and increasing global immunization initiatives. According to Fortune Business Insights, the global DTP vaccines market was valued at USD 11.69 billion in 2025. The market is projected to grow from USD 13.44 billion in 2026 to USD 46.46 billion by 2034, registering a strong CAGR of 16.77% during the forecast period. In 2025, North America dominated the global market with a share of 40.92%, supported by high vaccination coverage and a strong healthcare infrastructure.

DTP vaccines are combination vaccines that protect against three serious bacterial infections-diphtheria, tetanus, and pertussis. These vaccines are widely administered to infants, children, adolescents, adults, and pregnant women in various forms such as DTaP, Tdap, and DT/Td vaccines. The severe complications associated with these diseases, including pneumonia, seizures, airway obstruction, and muscle spasms, have significantly increased the demand for preventive vaccination globally.

Market Dynamics

Market Drivers

The rising prevalence of bacterial respiratory infections is a major factor driving market growth. Pertussis, caused by Bordetella pertussis, is highly contagious and poses a significant risk to infants and young children. The increasing number of reported pertussis cases globally has shifted focus toward timely vaccination and booster doses. Growing emphasis on pediatric immunization schedules and active government participation in vaccination programs are further supporting market expansion.

Market Restraints

Despite strong growth drivers, the market faces challenges due to vaccine hesitancy and lack of awareness regarding immunization schedules, particularly in low-income and developing regions. Religious beliefs, misinformation regarding vaccine safety, and inadequate healthcare infrastructure contribute to missed doses and incomplete immunization, restricting market growth and increasing the risk of disease outbreaks.

Market Opportunities

Government-led vaccination initiatives present significant growth opportunities for the market. Several countries are strengthening national immunization programs to improve vaccine coverage among infants, children, and adults. Global alliances and organizations are also introducing booster programs and combination vaccines to reduce disease burden and healthcare costs. These initiatives are expected to enhance vaccine adoption and support market growth through 2034.

Market Challenges

Limited cold chain infrastructure remains a major challenge, particularly in resource-limited regions. DTP vaccines require strict temperature control throughout storage and transportation. Inadequate refrigeration facilities and unreliable logistics often lead to vaccine wastage, reduced potency, and increased operational costs, thereby restraining market growth.

DTP Vaccines Market Trends

Technological advancements in vaccine development are shaping the future of the DTP vaccines market. Traditional chemically inactivated vaccines are associated with reduced immunogenicity and the need for multiple booster doses. As a result, manufacturers are increasingly shifting toward recombinant vaccine technologies that offer improved safety, stronger immune responses, and longer-lasting protection. These innovations are expected to significantly influence market growth during the forecast period.

Segmentation Analysis

By technology, the inactivated vaccines segment dominated the market, driven by the wide availability of approved products and high global vaccination coverage. However, recombinant and other advanced technologies are expected to grow at a notable rate due to increasing research and development activities.

By type, the DTaP vaccine segment held the largest market share, supported by its widespread use in pediatric immunization programs. The Tdap segment accounted for a substantial share due to its role as a booster vaccine for adolescents, adults, and pregnant women.

By age group, the pediatric segment dominated the market, owing to strong recommendations for early-life immunization and higher disease risk among children. The adult segment also contributed significantly due to routine booster doses and maternal immunization programs.

By distribution channel, government suppliers accounted for the largest share, driven by national immunization programs and bulk procurement of vaccines. Hospital and retail pharmacies are expected to grow steadily due to improved access and convenience.

Regional Outlook

North America dominated the market in 2025, supported by high disease awareness, strong immunization coverage, and the presence of key market players.

Asia Pacific held the second-largest share and is expected to grow at the highest CAGR due to increasing disease prevalence, government vaccination campaigns, and affordable vaccine availability.

Europe maintained a substantial market share, driven by advanced healthcare systems and structured immunization programs.

Latin America and the Middle East & Africa are expected to grow steadily due to rising vaccination initiatives and increasing efforts to eliminate vaccine-preventable diseases.

Competitive Landscape

The market is consolidated, with major players such as GSK plc, Sanofi, and Merck & Co., Inc. holding a significant share. Other notable players include Serum Institute of India, BioNet-Asia, and Wuhan Institute of Biological Products. These companies are focusing on product innovation, strategic collaborations, and regulatory approvals to strengthen their global presence.

Conclusion

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is set for substantial growth over the forecast period, supported by rising bacterial disease prevalence, expanding immunization programs, and continuous advancements in vaccine technologies. With the market valued at USD 11.69 billion in 2025, projected to reach USD 13.44 billion in 2026 and USD 46.46 billion by 2034, increasing government initiatives, pediatric immunization focus, and recombinant vaccine development are expected to sustain long-term market expansion despite challenges related to vaccine awareness and cold chain limitations.

Segmentation By Technology

  • Inactivated
  • Others

By Type

  • DTaP Vaccine
  • Tdap Vaccine
  • DT/ Td vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. DTaP Vaccine
    • 5.2.2. Tdap Vaccine
    • 5.2.3. DT/ Td vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. DTaP Vaccine
    • 6.2.2. Tdap Vaccine
    • 6.2.3. DT/ Td vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. DTaP Vaccine
    • 7.2.2. Tdap Vaccine
    • 7.2.3. DT/ Td vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. DTaP Vaccine
    • 8.2.2. Tdap Vaccine
    • 8.2.3. DT/ Td vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. DTaP Vaccine
    • 9.2.2. Tdap Vaccine
    • 9.2.3. DT/ Td vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. DTaP Vaccine
    • 10.2.2. Tdap Vaccine
    • 10.2.3. DT/ Td vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boryung Biopharma Co.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Serum Institute of India Pvt. Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BioNet-Asia.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Biological E Limited.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2033
  • Table 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 12: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 13: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 14: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 17: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 22: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 24: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 27: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group 2025 & 2034
  • Figure 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 11: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 12: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 13: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 18: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 19: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 20: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 21: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 22: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 23: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 26: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 27: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 28: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 29: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 31: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 33: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 36: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 37: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 38: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 39: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 40: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 41: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 43: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 46: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 47: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 49: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 50: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 51: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 53: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 56: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 57: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Share (%), By Company, 2025